(-0.01%) 5 478.00 points
(-0.04%) 38 803 points
(0.04%) 19 929 points
(0.27%) $80.55
(1.15%) $2.82
(0.17%) $2 332.90
(-0.29%) $29.31
(-0.10%) $969.90
(0.02%) $0.932
(-0.15%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy...
Stats | |
---|---|
Šios dienos apimtis | 7.11M |
Vidutinė apimtis | 6.03M |
Rinkos kapitalizacija | 183.53M |
EPS | $-0.660 ( Q3 | 2023-11-07 ) |
Kita pelno data | ( $-0.650 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.510 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00100 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-10 | Sterling O. James | Buy | 0 | |
2024-06-03 | Klima Thomas J | Sell | 3 834 | Common Stock |
2024-03-01 | Colvin Richard A | Buy | 199 000 | Stock Option (right to buy) |
2024-03-01 | Colvin Richard A | Sell | 6 770 | Common Stock |
2024-03-01 | Vittiglio Joseph | Buy | 199 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
92.55 |
Last 94 transactions |
Buy: 3 237 593 | Sell: 218 545 |
Tūris Koreliacija
bluebird bio Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
MAYHX | 0.898 |
PLFLX | 0.894 |
CHEF | 0.894 |
NMSSX | 0.892 |
PLFRX | 0.879 |
LGCL | 0.876 |
ATGL | 0.863 |
PLFDX | 0.859 |
AHTFX | 0.849 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
CCSB | -0.928 |
AILEW | -0.924 |
GECCI | -0.905 |
OPTZ | -0.884 |
BOTT | -0.883 |
PQTIX | -0.868 |
PQTAX | -0.868 |
MTEN | -0.864 |
NEWZ | -0.826 |
COCH | -0.824 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
bluebird bio Inc Koreliacija - Valiuta/Žaliavos
bluebird bio Inc Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $3.60M |
Bruto pelnas: | $-6.48M (-180.15 %) |
EPS: | $-3.39 |
FY | 2022 |
Pajamos: | $3.60M |
Bruto pelnas: | $-6.48M (-180.15 %) |
EPS: | $-3.39 |
FY | 2021 |
Pajamos: | $3.66M |
Bruto pelnas: | $-35.20M (-961.09 %) |
EPS: | $-11.89 |
FY | 2020 |
Pajamos: | $250.73M |
Bruto pelnas: | $245.34M (97.85 %) |
EPS: | $-9.95 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.